Nowroozi Ali, Karimi Amirali, Alilou Sanam, Amini Erfan
Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Urol J. 2021 Jan 10;18(3):349-350. doi: 10.22037/uj.v16i7.6526.
Prostate Cancer (PCa) is the most prevalent cancer in men. Radical Prostatectomy (RP) as a primary definitive treatment may be followed by adjuvant or salvage radiotherapy. However, there are some uncertainties about receiving immediate adjuvant radiation after RP in men with adverse pathological features versus early salvage radiation therapy. Decipher is a novel genomic classifier and almost all studies have confirmed Decipher as a reliable predictor of metastasis, recurrence and mortality. With the aid of Decipher, clinicians are able to determine the need for adjuvant versus salvage radiotherapy. Decipher has the potential to reduce decisional conflicts in clinical recommendations, and is cost-effective. However, further investigations are required to prove Decipher's role in clinical outcome improvement in patients receiving Decipher-based course of treatment compared with those receiving usual care.
前列腺癌（PCa）是男性中最常见的癌症。根治性前列腺切除术（RP）作为主要的确定性治疗方法，术后可能会进行辅助放疗或挽救性放疗。然而，对于具有不良病理特征的男性在RP后立即接受辅助放疗与早期挽救性放疗相比，仍存在一些不确定性。Decipher是一种新型的基因组分类器，几乎所有研究都证实Decipher是转移、复发和死亡率的可靠预测指标。借助Decipher，临床医生能够确定辅助放疗与挽救性放疗的必要性。Decipher有可能减少临床建议中的决策冲突，且具有成本效益。然而，与接受常规治疗的患者相比，还需要进一步研究来证明Decipher在接受基于Decipher治疗方案的患者临床结局改善中的作用。
